FDA Approves LENALIDOMIDE — Mylan Pharmaceuticals Inc.

# FDA Approves Mylan's Generic Lenalidomide Mylan Pharmaceuticals Inc. received FDA approval for generic lenalidomide, a significant immunomodulatory drug used to treat multiple myeloma and other hematologic cancers, potentially opening the market to lower-cost alternatives and intensifying competition in the lenalidomide segment. The approval could substantially reduce treatment costs for patients and payers while pressuring branded alternatives' market share in the oncology space.